Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. - Wikidata - wikimedia - TriplyDB

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.

http://www.wikidata.org/entity/Q46729796

about

Endothelin receptor antagonists for pulmonary arterial hypertension Drug treatment of pulmonary hypertension in children Clinical safety, pharmacokinetics, and efficacy of ambrisentan therapy in children with pulmonary arterial hypertension.The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension.Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension.Long term combination treatment for severe idiopathic pulmonary arterial hypertension The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases Non-congenital heart disease associated pediatric pulmonary arterial hypertension Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study.Risk assessment of mechanism-based inactivation in drug-drug interactions.Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review.Acute haemodynamic response in relation to plasma vardenafil concentrations in patients with pulmonary hypertension A New Era in Medical Management of Severe Pediatric Pulmonary Arterial Hypertension.Pediatric Cardiac Intensive Care Society 2014 Consensus Statement: Pharmacotherapies in Cardiac Critical Care Pulmonary Hypertension.2014 Guidelines of Taiwan Society of Cardiology (TSOC) for the Management of Pulmonary Arterial Hypertension.Updated evidence-based treatment algorithm in pulmonary arterial hypertension.Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.Safety and tolerability of bosentan in the management of pulmonary arterial hypertension.Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics.Tadalafil for the treatment of pulmonary arterial hypertension.Emerging drugs for pulmonary hypertension.Bosentan for the treatment of adult pulmonary hypertension.Tadalafil for the treatment of pulmonary arterial hypertension.Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension.Tadalafil for the treatment of pulmonary arterial hypertension.ADMET considerations for phosphodiesterase-5 inhibitors.Tadalafil: in the treatment of signs and symptoms of benign prostatic hyperplasia with or without erectile dysfunction.Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension.Evolving management of pediatric pulmonary arterial hypertension: impact of phosphodiesterase inhibitors.Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.Drug-drug interactions of cytostatics with regular medicines in lung cancer patients.Substrate-specific pharmacokinetic interaction between endothelin receptor antagonists and phosphodiesterase-5 inhibitors--assembling the clues.A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK.High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension.Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension.Safety and effectiveness of tadalafil in pediatric patients with pulmonary arterial hypertension: a sub-group analysis based on Japan post-marketing surveillance.Conversion from sildenafil to tadalafil: results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) study.

P2860

Q24200714-CADE4B0E-3EDB-4268-9D64-DF90DAA56023 Q26996078-9525E91E-7404-4A5D-B9B4-F9BF96C9E49F Q33161210-DA90E36B-1C05-4782-8970-41B49B9FAA62 Q33844740-37B9BA64-20A7-43B8-97EC-713DF6A1FFDC Q33892575-ADE00DF1-89FA-4272-880F-8BDF44900710 Q34390545-08EA0E41-5784-402A-8DC6-4CF40D43D1EA Q35156618-0749A916-9874-4F47-9EFB-190E5B8D5CBD Q35165691-34381C9F-D4BD-4328-910E-059EB3720EAB Q35620058-0CED33F4-DD19-436B-8584-12C20B235C96 Q36174265-4CA3FB35-F8CE-4259-A4BF-5D4B966B9A60 Q36257077-1A1E7890-290B-4713-9D12-475CA5B72C2E Q36468138-3CBF4A1A-38EC-4B5C-937C-BBB70367A290 Q36481525-838A7376-EE6D-455C-AAA6-F7C107BA643D Q36763080-DB5E36BC-3006-4ED9-B0C3-D59D485D62D8 Q36777766-0B0980C7-5894-4769-9422-B803B0A070A9 Q36939543-C5E4C07B-0194-4F13-9F1C-F432FD7B6C76 Q37302470-5AC4E6A6-0D27-45C9-868A-F56171FF5C76 Q37403190-2774E670-7124-4629-A3B9-5CF4D806302C Q37420916-BB50D760-FB07-4CC3-9601-959A4175A58E Q37650325-3D308E5B-CD82-4396-BF75-4359FBEAA02D Q37679940-3F82A5A5-27DD-49DB-8CDF-44F0331FA98B Q37822722-AC309E86-AA40-449E-AC00-D4D149123441 Q37894086-851B5BF5-163B-4094-86A2-4F59437769F9 Q37972127-DD2A03E9-71B2-4466-9920-1CD3C6F5E432 Q37987260-4874D92C-01EF-4BCF-8C32-996D40692443 Q38024409-C3BED202-4707-4337-9349-39A63AB8210E Q38047228-014902F9-885B-4D66-A00C-81CDB924F273 Q38058056-F79BD910-259B-4DAF-A5D3-763E3A7CE79B Q38068345-2D750261-BC55-49CC-ADF6-466AB57E936C Q38325919-D341599E-7EE6-4571-9728-5B398E1DC731 Q38928924-70F1B479-4149-42E3-A612-BCD0DBC9CEB2 Q43132024-D6070CB9-6F8F-43FA-A512-224D3CD90D09 Q46262285-5D370558-C7D8-4159-8DFE-61B37657F3C6 Q50672722-3053714A-4ABF-4945-BC55-4B0BD14CEC3A Q50793400-E296E098-4E0D-4210-B9E7-ACB3C99B77C7 Q51747400-CE587F0D-32E9-4977-94F3-B990A922B9DC Q51842114-BE5EFC91-E3F8-4C2E-B80A-7DA6A8BE423A Q53286047-BA4DA45F-F3E4-4833-8807-3FE22609CC0B

P2860

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.

http://www.wikidata.org/entity/Q46729796

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.

@en

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.

@nl

type

label

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.

@en

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.

@nl

prefLabel

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.

@en

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.

@nl

P1433

Q46729796-D2599F74-228A-4664-888E-AA48A74D7854

P1476

Q46729796-B79A9380-CA0D-473E-8619-F9634D450DA0

P2093

Q46729796-4029C45E-C875-40E7-A43A-5C4E416C92E9

Q46729796-7C489BE7-C9F3-463C-8212-A3A7CA86A4C9

Q46729796-7CB93E04-B97E-408B-99F2-45E37A2591EF

Q46729796-CF10A0B9-EF61-48B8-96DE-96E452BE0812

Q46729796-D0C4C53D-C6AD-4D56-B6EA-E77DE737E94D

Q46729796-E0FAE725-7D81-43E2-9310-2AF5FB7E311A

P2860

Q46729796-01717FBD-91A1-4051-B4FD-4FC7FD193897

Q46729796-10FBF00A-856F-4314-9E4C-FD40A4D8ECDF

Q46729796-1EE187C0-5CFA-42B4-913F-CB1E6E94B844

Q46729796-21069A25-BBD0-4AB8-B4B0-F699FCEA8A9C

Q46729796-2E361A3D-C92A-460F-BFEF-8C16CE0DBF37

Q46729796-306C7CD6-CB3E-4750-B876-DFCCDE0700C3

Q46729796-3647C0CC-DC7E-4861-BBF6-29EDCC4BC867

Q46729796-39A369C0-718E-4EF3-8F41-DF4503DBCA1C

Q46729796-4EFFF571-EF3E-478C-B495-B6D796CB2E36

Q46729796-515C90EC-E52D-426D-9EB4-FF9FB2607C71

P304

Q46729796-3DEEC580-455E-4F34-9DE4-0C84761BC018

P31

Q46729796-9908D075-E013-49C7-B6BC-14D09F497F73

P356

Q46729796-440A3C74-6A0F-419A-8AC1-FA5CFF7F4A39

P433

Q46729796-5B5B5398-D90F-41CF-8C05-518A9CAE5BF4

P478

Q46729796-FC9B2405-D8EA-4D95-A65E-F7F1F84973FD

P577

Q46729796-79A723A5-7EC4-4976-AB45-0A0543475E16

P5875

Q46729796-F419C6CB-DDC1-4591-BE0B-B2C9CE11659D

P698

Q46729796-F10CA1DD-013A-4777-B199-F08232E2F6B5

P356

0091270008315315

P1433

The Journal of Clinical Pharmacology

P1476

Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects.

@en

P2093

Albert Yu

http://www.w3.org/2001/XMLSchema#string

Christelle Darstein

http://www.w3.org/2001/XMLSchema#string

Diane L Phillips

http://www.w3.org/2001/XMLSchema#string

Jasper Dingemanse

http://www.w3.org/2001/XMLSchema#string

Malcolm I Mitchell

http://www.w3.org/2001/XMLSchema#string

Rebecca E Wrishko

http://www.w3.org/2001/XMLSchema#string

P2860

Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial

Inhaled iloprost for severe pulmonary hypertension.

Pathology and pathophysiology of primary pulmonary hypertension.

Sildenafil citrate therapy for pulmonary arterial hypertension.

Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil.

Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension

Tadalafil pharmacokinetics in healthy subjects

Clinical pharmacology of bosentan, a dual endothelin receptor antagonist.

The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study.

P304

610-618

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270008315315

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2008-02-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5547599

http://www.w3.org/2001/XMLSchema#string

P698

18305126

http://www.w3.org/2001/XMLSchema#string